Vinorelbine

Glioblastoma

National Cancer Institute (NCI)Phase 2/3Active

B

56/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 52/ 100
Competitive Position: 65/ 100

Competitive context

233 Active assets in the Glioblastoma cohort.

Asset / Sponsor	Phase	Rating
(+)-VINCRISTINE University of Cincinnati	Phase 3	BB
Irinotecan University of Cincinnati	Phase 3	BB
Lomustine Telix Pharmaceuticals (Innovations) Pty Limited	Phase 3	BB
Enzastaurin Denovo Biopharma LLC	Phase 3	BB
Inno-206 Université de Sherbrooke	Phase 2	BB

View all 50 →

Same molecule, other indications

Vinorelbine is also rated in:

HER2 positive breast carcinomaDormant

BBB

Indicative ·

74 / 100

Recurrent Breast CarcinomaDormant

BBB

Indicative ·

72 / 100

Hodgkins lymphomaDormant

BBB

Indicative ·

72 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.